





Mirco Pistelli Clinica di Oncologia Medica ^. O. U. Ospedali Riuniti Ancona




Presidente del convegno: Stefania Gori

Convegno Interregionale Marche-Umbria


ANCONA, 2 ottobre 2019 Auditorium "S. Totli" Ospedali Riuniti di Ancona

LA GESTIONE DELLA PAZIENTE CON CARCINOMA MAMMARIO

Terapia endocrina di associazione con inibitori di CDK 4/6: **Novità per la paziente in pre-menopausa**



ER+ HER2- MBC: a story of success?



- Despite the advances over the years, patients on endocrine therapy still have recurrence of their disease
 - EBC: recurrences either during or after adjuvant endocrine treatments 10-15% @5yrs and up to 30% @15yrs
 - MBC: endocrine treatments lead to initial tumour regression in only ~30% plus 20% of prolonged stable disease, inevitably resistant disease develops in almost all pts





Original Research

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort



Methods: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014). Of 16,680 eligible patients, 15,085 had full immunohistochemistry data, allowing classification as hormone receptor-positive and HER2-negative (HR+/HER2-, N = 9907), HER2-positive (HER2+, N = 2861) or triple-negative (HR-/HER2-, N = 2317) subcohorts. Multivariate analyses of OS were conducted among the full ESME cohort and subcohorts.







Period	2008	2009	2010	2011	2012	2013
Median OS	3.12	2.94	3.09	3.23	3.09	3.29
(95% CI)(yrs)	[2.92-3.31]	[2.78-3.09]	[2.94-3.24]	[3.02-3.48]	[2.89-3.25]	[3.09-ND]

MBC: what about age?

ABC in premenopausal patients

-~19% of invasive breast cancers are diagnosed in women aged ≤49 years¹

The proportion of patients aged <50 years may be up to 42% in the Asia-Pacific region²

 1. Desantis CE, et al. CA Cancer J Clin 2017;t; 2. Youlden DR, et al. Cancer Biol Med 2014;11:101–115;

MBC: US epidemiology

	BC deaths		MBC incidence		MBC prevalence	
	Age 15-99	Age 15-49	Age 15-99	Age 15-49	Age 15-99	Age 15-49
2013	42200	4000 (10%)	50000	7000 (14%)	139000	20000 (14%)
2017	45000	4300 (10%)	54400	7100 (13%)	154000	20700 (13%)


Mariotti, Cancer Epid Biom Prev 2017;

MBC: Italy epidemiology

età (anni)	Casi incidenti (de novo)	Tutti i casi ind (de novo + evol		Casi prevalenti (de novo)	Tutti i casi preva (de novo + evolu	
15-39	100	400	1	300	800	
40-49	300	1200	11%	1100	3700	12%
50-59	600	2000		1800	6200	
60-69	700	2600		2500	8300	
70-79	900	3000		2500	8800	
80-99	800	4800		2000	9300	
15-99	3400	14000		10200	37100	

TABELLA 29. Stima dei casi di tumore della mammella metastatici nel 2014, sia incidenti che prevalenti, sia metastatici all'esordio che successivamente. Da Crocetti et al.³


EBC: prognosis by age groups (1)



Azim HA Jr, et al. Clin Cancer Res. 2012;18:(5):1341-1351.

EBC: prognosis by age groups (2)

SOFT/TEXT BCFI According to Age



BCFI, breast cancer-free interval

Regan MM, et al. J Clin Oncol. 2016;34:(19):2221-2231.

EBC: prognosis by age groups (3)

Age and Rate of Distant Recurrence After ER+ EBC in First 5 Years and Years 5-20

	Years 0-5 (on endocrine, 74,194 women)				Years 5-20 (off endocrine, 62,923 women)				
	Events	Women			RR (95% CI)	Events	Women		RR (95% CI)
Analyses g	jiven TN st	tatus:	8					Ĩ	
Age at diag	gnosis (yea	ars)							
<35	338	1585		-	2.18 (1.96-2.43)	114	1009	3 	1.51 (1.26-1.83)
35-44	1288	10344			1.22 (1.15-1.29)	623	7859	+	1.00 (0.92-1.09)
45-54	2017	22568	363		0.88 (0.84-0.92)	1267	19326	-	0.86 (0.81-0.91)
55-64	2430	25439			0.97 (0.93-1.02)	1736	22337	-	1.04 (0.99-1.09)
65-74	1267	14258	-		0.95 (0.8 <mark>9-1.01</mark>)	957	12392		1.12 (1.04-1.20)


EBC, early breast cancer

Pan H, et al. N Engl J Med. 2017;377:(19):1836-1846.

Adverse Histopathologic Features More Common in Young Women

- Symptomatic/higher-stage disease at presentation
- HER2-positive tumours
- PR-negative tumours
- High-grade tumours
- High Ki67 (proliferation)
- p53 mutations
- EGFR-overexpression
- Extensive intraduct component (EIC)

MBC: prognosis by age groups (1)



Chen MT, 2017

MBC: prognosis by age groups (2)

Table 2. Number of women, median overall and relative survival in months and 5-year relative survival in percentage (95% confidence interval) for women diagnosed with *de novo* stage IV breast cancer in the SEER-11 areas by grouped age and year at diagnosis

	Year Age, y N Overall Relative survival					
Year			Overall Relative survival		5-y relative survival (95% CI)	10-y relative survival (95% CI)
1992-1994	15-49	430	22.2	22.3	18% (14%-21%)	10% (8%-14%)
1992-1994	50-64	777	18.4	19.1	15% (13%-18%)	8% (6%-11%)
1992-1994	65-74	598	16	17.6	15% (12%-18%)	7% (5%-10%)
1992-1994	75-84	442	10.1	10.9	16% (12%-20%)	7% (4%-11%)
1992-1994	85+	168	3.8	4.1	6% (2%-13%)	4% (0%-16%)
1992-1994	All ages	2,415	15.7	16.7	15% (14%-17%)	8% (7%-9%)
1995-1999	15-49	894	24.5	24.7	24% (21%-27%)	11% (9%-13%)
1995-1999	50-64	1,321	20.3	20.6	21% (18%-23%)	10% (8%-12%)
1995-1999	65-74	978	14.4	15.2	17% (15%-20%)	6% (5%-8%)
1995-1999	75-84	799	10.4	11.8	13% (10%-16%)	7% (5%-10%)
1995-1999	85+	292	4.7	5.5	16% (10%-23%)	8% (2%-21%)
1995-1999	All ages	4,284	16.5	17.7	19% (17%-20%)	8% (8%-9%)
2000-2004	15-49	1,307	29	29.3	29% (26%-31%)	14% (12%-16%)
2000-2004	50-64	2,270	24.6	25.1	24% (23%-26%)	11% (10%-13%)
2000-2004	65-74	1,319	18.9	20.3	20% (18%-23%)	8% (6%-10%)
2000-2004	75-84	1,142	10.3	11.4	15% (13%-18%)	8% (6%-10%)
2000-2004	85+	436	5.7	7.2	14% (9%-20%)	9% (3%-19%)
2000-2004	All ages	6,474	19.8	21.1	22% (21%-23%)	10% (9%-11%)
2005-2012	15-49	2,748	38.4	38.7	36% (34%-38%)	-
2005-2012	50-64	4,861	29	29.7	25% (24%-27%)	-
2005-2012	65-74	2,468	23.3	24.5	24% (22%-26%)	-
2005-2012	75-84	1,820	12	14	18% (16%-21%)	-
2005-2012	85+	865	6	8.2	13% (9%-17%)	-
2005-2012	All ages	12,762	25.2	26.9	26% (25%-27%)	-

Abbreviation: CI, confidence interval.

Mariotto AB, 2017

Younger age is associated with a preferential use of chemo

Prognostic factor		Univariate			Multivariate	
	OR	95% CI	р	OR	95% CI	р
Age ≤65 years >65 years	1 (ref) 0.33	0.21-0.53	<0.001	1 (ref) 0.29	0.17-0.49	<0.001
Menopausal status premenopause postmenopause	1 (ref) 0.40	0.24-0.66	0.004	rfm*	1	0.102
De novo metastatic disease no yes	1 (ref) 2.92	1.64-5.17	<0.001	1 (ref) 2.89	1.54-5.44	0.001
Number of metastatic sites 1 2 ≥3	1 (ref) 2.05 2.91	1.17-3.57 1.59-5.34	0.001	rfm -	-	0.400
Metastasis type non-visceral visceral	1 (ref) 5.15	3.09-8.57	<0.001	1 (ref) 5.80	3.34-10.06	<0.001
DDFS ≤median of 36.3 months >median of 36.3 months	1 (ref) 0.48	0.30-0.76	0.002	rfm	:	0.412

Table 3: Prognostic factors associated with a preferential use of CT as first-line treatment of MBC

Abbreviations: *rfm, removed from the final model

Bighin C, Oncotarget 2017


ABC in premenopausal patients

 Endocrine therapy with ovarian suppression is the recommended first-line treatment for premenopausal women with HR+, HER2– ABC;¹⁻⁴

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines*) for Breast Cancer. V.3.2017;

- 2. Rugo HS, et al. J Clin Oncol 2016;34:3069-3103;
- 3. Cardoso F, et al. Ann Oncol 2017;28:16-33;
- 4. LG Aiom www.aiom.it

Single vs. Combination Endocrine Therapy in Premenopausal Women with Metastatic Breast Cancer: OS



Klijn JG, et al. JNCI 2000; 92:903-11.

CDK inhibitors


CDK	1 st line	Progression on ET	Later line
Palbociclib	PALOMA-2 (Letrozole)	PALOMA-3* (Fulvestrant)	
Ribociclib	MONALEESA-2 (Letrozole)		
	MONALEESA-3 (Fulvestrant)	MONALEESA-3 (Fulvestrant)	
	MONALEESA-7*		
Abemaciclib	MONARCH-3 (NSAI)	MONARCH-2* (Fulvestrant)	MONARCH-1 (None)

*Included premenopausal patients with ovarian suppression

This presentation is the intellectual property of the presenter. Contact them at roomo/2@jhmi.edu for permission to reprint and/or distribute.

"Endocrine therapy plus a CDK 4-6 inhibitor, is the preferred option for hormone receptor positive disease, even in the presence of visceral disease, unless there is visceral crisis or concern/proof of endocrine resistance"

Defining endocrine sensitivity



Endocrine Sensitive: Premenopausal pts

Phase III MONALEESA-7 Trial of Premenopausal Patients With HR+/HER2- Advanced Breast Cancer Treated With Endocrine Therapy ± Ribociclib: Overall Survival Results

Sara Hurvitz,¹ Seock-Ah Im,² Yen-Shen Lu,³ Marco Colleoni,⁴ Fabio Franke,⁵ Aditya Bardia,⁶ Nadia Harbeck,⁷ Louis Chow,⁸ Joohyuk Sohn,⁹ Keun Seok Lee,¹⁰ Saul Campos-Gomez,¹¹ Rafael Villanueva Vazquez,¹² Kyung Hae Jung,¹³ Arunava Chakravartty,¹⁴ Gareth Hughes,¹⁵ Ioannis Gounaris,¹⁵ Karen Rodriguez Lorenc,¹⁴ Tetiana Taran,¹⁴ Debu Tripathy¹⁶

¹UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; ²Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ³National Taiwan University Hospital, Taipei, Taiwan; ⁶Division of Medical Senology, Istituto Europeo di Oncologia, Milan, Italy; ³Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil; ⁶Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA, ⁷Department of Obstetrics and Gynecology, Breast Center, Ludwig-Maximilians-University Munich, Munich, Germany; ⁸Organisation for Oncology and Translational Research, Hong Kong; ⁹Severance Hospital, Yonsei University Health System, Seoul, Korea; ¹⁰Center for Breast Cancer, National Cancer Center, Gyeunggi-do, Korea; ¹¹Cantro Oncológia, Hospital de Sant Joan Despi Moisès Broggi, Barcelona, Spain; ¹³Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ¹⁵Novartis Pharmaceuticals Corporation, Basel, Switzerland; ¹⁶The University of Texas MD Anderson Cancer Center, Houston, TX, USA

22

PRESENTED AT:


2019 A

ANNUAL MEETING

#ASCO19 littles are the property of the au permission regulated for reque

PRESENTED BY: Dr Sara Hurvitz

MONALEESA-7 Study Design



- Prior chemotherapy (yes/no)
- Combination partner (NSAI/TAM)

ANA, anastrozole; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; FSH, follicle-stimulating hormone; GOS, goserelin; HRQOL, health-related quality of life; NSAI, nonsteroidal aromatase inhibitor; ORR, objective response rate; TAM, tamoxif TTDD, time to definitive deterioration.

* Premenopausal status was defined as either patient had last menstrual period ≤ 12 months or if receiving TAM or toremifene for ≤ 14 days, plasma estradiol and FSH must be in normal premenopausal range or in the case of induced amenorrhea, plasma estradiol and FSH must be in normal premenopausal range. Perimenopausal status was defined as neither premenopausal nor postmenopausal (prior bilateral oophorectomy, age ≥ 60 years, or FSH and plasma estradiol ievels in normal postmenopausal range). Patients could not be ≥ 60 years of age. * Patients who received ≤ 14 days of NSAI/TAM ± GOS were allowed. < TAM and NSAI were administered daily orally. TAM dose was 20 mg, LET dose was 2.5 mg, and ANA dose was 1 mg, ⁴ GOS 3.6 mg was administered by subcutaneous injection.



PRESENTED BY: Dr Sara Hurvitz

Statistical Methods

- A hierarchical testing strategy was used; OS to be tested under a 3-look group sequential design only if PFS results were positive
- PFS improvement was statistically significant during the primary analysis
 - Median PFS was 23.8 months in ribociclib + ET arm and 13.0 months in ET only arm (HR, 0.55 [95% CI, 0.44-0.69]; P < .0001)
- OS was the key secondary endpoint; this prespecified interim analysis took place after 192 deaths
- Prespecified Lan DeMets (O'Brien-Fleming) stopping boundary for claiming superior efficacy was defined as P ≤ .01018
- Study had 80% power to detect a difference in OS



Key Patient Baseline Characteristics

	Ribociclib + ET (n = 335)	Placebo + ET (n = 337)
Age (range), years	43 (25-58)	45 (29-58)
Race, n (%) White Asian Black Other/unknown	187 (56) 99 (30) 10 (3) 39 (12)	201 (60) 99 (29) 9 (3) 28 (8)
ECOG PS, n (%) ^a 0 1 2	245 (73) 87 (26) 0	255 (76) 78 (23) 1 (< 1)
Previous neoadjuvant or adjuvant ET, n (%) No Yes	208 (62) 127 (38)	196 (58) 141 (42)
Previous chemotherapy for advanced disease, n (%)	47 (14)	47 (14)

* Data were missing for 3 patients in each arm.

2019 ASCO

ANNUAL MEETING

#ASCO19

Rides are the property of the author permission required for reuse.

PRESENTED BY: Dr Sara Hurvitz

Patient Disposition at Interim Analysis Data Cutoff Median follow-up of 34.6 months

	Ribociclib + ET (n = 335)	Placebo + ET (n = 337)	All Patients (N = 672)
Patients treated, n (%)	335 (100)	337 (100)	672 (100)
Treatment ongoing	116 (35)	57 (17)	173 (26)
End of treatment	219 (65)	280 (83)	499 (74)
Reason for end of treatment, n(%)			
Adverse event	11(3)	13 (4)	24 (4)
Lost to follow-up	2(< 1)	0	2 (< 1)
Physician decision	10 (3)	22 (7)	32 (5)
Disease progression	173 (52)	230 (68)	403 (60)
Protocol deviation	0	2 (< 1)	2 (< 1)
Patient/guardian decision	20 (6)	10 (3)	30 (4)
Death	3 (< 1)	3 (< 1)	6 (< 1)


PRESENTED AT:

2019 ASC

#ASCO19 Sides are the property of the author permission required for result.

PRESENTED BY: Dr Sara Hurvitz

Primary Analysis (PFS)



Ribockillib group 335 (0) 301 (9) 264 (12) 264 (15) 245 (20) 235 (23) 219 (25) 178 (55) 136 (88) 90 (124) 54 (156) 40 (170) 20 (187) 3 (202) 1 (203) 0 (204) Placebo group 337 (0) 273 (12) 248 (15) 230 (19) 207 (21) 183 (25) 165 (27) 124 (50) 94 (72) 62 (97) 31 (121) 24 (128) 13 (138) 3 (147) 1 (149) 0 (150)


Tripathy et al. Lancet 2018

This presentation is the intellectual property of the presenter. Contact them at rconno2034mi.adu for permission to reprint and/or distribute.

MONALEESA-7 Pre/Perimenopausal With Ovarian Suppression + Al or Tamoxifen With Placebo vs Ribociclib


PFS (Investigator Assessment)	Tamo	oxifen	NSAI		
115 (Investigator Assessment)	Ribociclib Arm n = 87	Placebo Arm n = 90	Ribociclib Arm n = 248	Placebo Arm n = 247	
Number of events, n	39	55	92	132	
Median PFS, months (95% CI)	22.1 (16.6–24.7)	11.0 (9.1–16.4)	27.5 (19.1–NR)	13.8 (12.6–17.4)	
Hazard ratio (95% CI)	0.585 (0.387-0.884)		0.569 (0.4	136-0.743)	

Tripathy D, et al. Lancet Oncol. May 24, 2018 [epub ahead of print].



- The CBR in patients with measurable disease was 79.9% for ribociclib + tamoxifen/NSAI vs 67.3% for placebo + tamoxifen/NSAI (p=0.000340)
- Overall survival data were immature at the cut-off date

Overall Survival



- ≈ 29% relative reduction in risk of death
- The P value of .00973 crossed the prespecified boundary to claim superior efficacy

Landmark Analysis

Kaplan-Meier Estimate	Ribociclib + ET	Placebo + ET
36 months	71.9%	64.9%
42 months	70.2%	46.0%


PRESENTED AT:

2019 ASCO ANNUAL MEETING HASCO19 Bilder are the property of the auto

PRESENTED BY: Dr Sara Hurvitz

Presented By Sara Hurvitz at 2019 ASCO Annual Meeting

Overall Survival in the NSAI Subgroup



≈ 30% relative reduction in risk of death

Landmark Analysis

Kaplan-Meier Estimate	Ribociclib + ET	Placebo + ET
36 months	72.2%	64.6%
42 months	69.7%	43.0%

PRESENTED AT:

2019 ASCO ANNUAL MEETING

PRESENTED BY: Dr Sara Hurvitz

Subsequent Therapies After Treatment Discontinuation

First Subsequent Therapy

	Ribociclib + ET (n = 335)	Placebo + ET (n = 337) 280 205 (73)	
Patients who discontinued study treatment, n	219		
Any medication, n (%) ^a	151 (69)		
Chemotherapy alone	49 (22)	80 (29)	
Chemotherapy + hormone therapy/other	18 (8)	22 (8)	
Hormone therapy alone	49 (22)	57 (20)	
Hormone therapy + other	31 (14)	41 (15)	
Other	4 (2)	5 (2)	

- Receipt of any subsequent CDK4/6 inhibitors in patients who discontinued study treatment
 - Ribociclib arm: 22/219 patients (10%)
 - Placebo arm: 52/280 (19%)

* Percentages are based on the number of patients who discontinued treatment.

PRESENTED AT

2019 A



PRESENTED BY: Dr Sara Hurvitz

Overall Survival Subgroup Analysis

 Consistent OS benefit seen within subgroups

S	No. of Patients (%)	HR for Death (95% CI)
All patients	672 (100)	0.712 (0.535-0.948
Endocrine combination partner TAM + GOS NSAI + GOS	177 (26.3) H 495 (73.7) H	0.791(0.454-1.377 0.699(0.501-0.976
Age ≪ 40 years ≥ 40 years	186 (27.7) H 486 (72.3) H	0.788 (0.476-1.304 0.685 (0.481-0.976
Race Asian Non-Asian	198 (29.5) + + + + + + + + + + + + + + + + + + +	0.395 (0.218-0.716 0.911 (0.636-1.303
Prior CT in a metastatic setting Yes No	94(14.0) + 578(86.0) +	0.665 (0.328 1.346 0.731 (0.535-0.999
Adjuvant or neoadjuvant CT* Yes No	276 (41.1) 302 (44.9)	0.907 (0.605-1.359 0.541 (0.323-0.907
Adjuvant or neoadjuvant hormonal therapy Yes No	268 (39.9) 404 (60.1) ►	0.911(0.597-1.389 0.675(0.453-1.004
Region Asia Europe and Australia Latin America North America Other	180 (26.8) 275 (40.9) 56 (8.3) 97 (14.4) 64 (9.5)	0.429 (0.235-0.783 0.973 (0.624-1.517 0.630 (0.234.1697 0.865 (0.399-1.874 0.865 (0.399-1.874
Lung or liver involvement Yes No	342 (50.9) 330 (49.1)	0.726 (0.500-1.054 0.698 (0.477-1.090
Bane lesion only Yes No	159 (23.7) F 513 (76.3) F	1.006 (0.526-1.926 0.654 (0.474-0.901
No. of metastatic sites < 3 2 3	436 (64.9) 236 (55.1)	0.852 (0.583 1.246 0.581 (0.371-0.910
Time from prior ET completion None Progression on/within 12 months of end of ET Progression > 12 months after end of ET	404 (60.1) ► 205 (30.5) ► 60 (8.9) ►	0.675 (0.453-1.004 0.805 (0.512-1.267 1.533 (0.440-5.339
	0.125 0.25 0.5	1 2 4 8


* In patients with no prior chemotherapy in the metastatic setting.

PRESENTED AT: 2019 ASCO

#ASCO19 Slider are the property of the author permitiples required for record

PRESENTED BY:

Time to First Subsequent Chemotherapy





2019 ASCO #ASCO Build or the property and the property an

SCO19 to are the property of the author, titulan required for revue.

PRESENTED BY: Dr Sara Hurvitz

Safety

- The median treatment duration was approximately 2 years in the ribociclib arm and approximately 1 year in the placebo arm
- After 15 months of additional follow-up, the adverse event profile for the ribociclib arm remained consistent with the known safety profile
- The rates of grade 3 or 4 adverse events of special interest in the ribociclib and placebo arms, respectively, were:
 - Neutropenia, 63.5% and 4.5%
 - Hepatobiliary toxicity, 11% and 6.8%
 - Prolonged QT interval, 1.8% and 1.2%

ASCO19

det are the property of the author


Reference: Tripathy D, et al. Loncet Oncol. 2018;19:904-915.

PRESENTED AT:


2019 A

TTD ≥10% IN GLOBAL HRQoL WAS DELAYED WITH RIBOCICLIB VS PLACEBO





Patients censored at progression; Similar results obtained with TTD ≥5%, ≥10%, and ≥15%.




Clinically meaningful reductions in EORTC QLQ-C30 pain score vs baseline were observed with ribociclib from Cycles 3-11 and 22-28^{1,2}



Patients cansored at progression; "p-value not calculated, 1. Osoba D et al. J Clin Oncol 1998;16:139–144; 2. Cocks K et al. Ew J Cancer 2012;48:1713–1721.

TTD ≥10% IN FATIGUE WAS DELAYED WITH RIBOCICLIB VS PLACEBO







*Patients censored at progression; *p-value not calculated.

Conclusions

- MONALEESA-7 is the only study to date to evaluate CDK4/6 inhibitors exclusively in premenopausal women
- Ribociclib plus ET resulted in a statistically significant longer OS compared with ET alone
 - Approximate 29% relative reduction in risk of death
 - Approximate 30% relative reduction in risk of death in the NSAI cohort
 - Treatment ongoing in 35% of patients in the ribociclib arm

lides are the property of the su

- The benefit of ribociclib extends beyond initial treatment based on time to subsequent chemotherapy and PFS 2
- This is the first time a statistically significant improvement in OS has been observed with a CDK4/6 inhibitor in combination with ET in patients with HR+/HER2- ABC


Endocrine Sensitive Disease in Premenopausal pts: Palbociclib and Abemaciclib

- HR+, HER2- ABC
- Postmenopausal

Noprior systemic therapy in this setting

- If neoadjuvant or adjuvant ET administered, a disease free interval of >12 months since completion of ET
- ECOG PS ≤1

Primary endpoint: Investigator-assessed PFS



4.1 Indicazioni terapeutiche

IBRANCE è indicato per il trattamento del carcinoma mammario localmente avanzato o metastatico positivo ai recettori ormonali (HR) e negativo al recettore del fattore di crescita epidermico umano 2 (HER2):

- in associazione ad un inibitore dell'aromatasi;
- in associazione a fulvestrant in donne che hanno ricevuto una terapia endocrina precedente (vedere paragrafo 5.1)

In donne in pre- o perimenopausa, la terapia endocrina deve essere associata ad un agonista dell'ormone di rilascio dell'ormone luteinizzante (LHRH).



4.1 Indicazioni terapeutiche


Verzenios è indicato per il trattamento di donne con carcinoma della mammella localmente avanzato o metastatico, positivo ai recettori ormonali (HR), negativo al recettore del fattore umano di crescita epidermico di tipo 2 (HER2) in associazione con un inibitore dell'aromatasi o fulvestrant, come terapia endocrina iniziale, o in donne che hanno ricevuto una precedente terapia endocrina.

MONARCH-3³

Nelle donne in pre- o perimenopausa, la terapia endocrina deve essere combinata con un agonista dell'ormone di rilascio dell'ormone luteinizzante (LHRH).


'FINN RS, et al. N Engl J Med 2016; "Hortobagyi G, et al. N Engl J Med 2016; "di Leo A, et al. J Clin Oncol 2017

Endocrine Resistant Disease



Modified from Johnston S. SABCS 2016

Progression after endocrine therapy




¹Turner NC, et al. N Engl J Med 2015; ²Slamon D et al, J Clin Oncol 2018; ³Sledge G, et al. J Clin Oncol 2017

Palbociclib + Fulvestrant in premenopausal women: a subset analysis of PALOMA-3 trial

PALOMA-3


- N=106
- Fulvestrant + goserelin
- HR 0.50 p=0.013



20% pts in premenopausal

5 <u>,</u>	Premenopausal		Postmenopausal	
	Palbociclib + Fulvestrant (n = 71)	Placebo + Fulvestrant (n = 36)	Palbociclib + Fulvestrant (n = 274)	Placebo + Fulvestrant (n = 136)
AEs, % ^{8,8}				
Any AEs	98.6	97.2	98.5	87.5
All grade 3/4 AEs	83.1	25.0	71.2	22.1
Any serious AEs	14.1	19.4	22.4	16.9
All grade 3/4 serious AEs	8.5	8.3	9.1	11.8
Dose modifications due to AEs, %				
Dose interruption	90.1	58.3	82.1	62.5
Dose reduction	42.3	2.8	31.8	1.5
Cycle delay	52.1	22.2	46.7	8.8
Discontinuation rate of palbociclib/placebo	5.6	o	4.7	3.7
Average daily dose of palbociclib,	/placebo, mg ^c			
Median (range)	125 (85-126)	125 (110-126)	125 (80-131)	125 (106-129

PALOMA-3 trial: OS




Abemaciclib + Fulvestrant in premenopausal women: a subset analysis of MONARCH-2 trial

17% pts in premenopausal

MONARCH-2

- N=114
- Fulvestrant + GnRH
- HR 0.45, p=0.002




	Abema + Fulv	Placebo + Fulv	HR (p-value) 0.553 (<0.0000001)	
Median PFS – ITT (n = 446; 223)	16.4 mo	9.3 mo		
Median PFS – Pre/perimenopausal with no prior AI (n = 62; 30)	Not reached	11.3 mo	0.451 (0.009)	

AI = aromatase inhibitor

Neven P et al. Proc ASCO 2018; Abstract 1002.

Monarch-2 trial: OS



OS: 46.7 mo vs 37.3 mo

Subgroup	No. of Patients	No. of Events	HR (95% CI)	Abemaciclib + Fulvestrant	Favors Placebo + Fulvestrant
Overall	669	338	0.757 (0.606-0.945)	-+-	
Nature of disease					
Visceral	373	210	0.675 (0.511-0.891)		
Bone only	180	76	0.907 (0.564-1.457)		
Other	113	52	0.928 (0.528-1.632)		
ET resistance					
Primary resistance	172	94	0.686 (0.451-1.043)		
Secondary resistance	458	241	0.787 (0.605-1.021)	-	
Menopausal status	CHERK	2200	250162000000000000		
Premenopausal or perimenopausal	114	44	0.689 (0.379-1.252)		
Postmenopausal	551	293	0.773 (0.609-0.980)		
Age group, years	10000	10000			
<65	424	200	0.710 (0.532-0.948)		
265	245	138	0.898 (0.638-1.263)		
Geographical region	1000	Seleta en	10311010033345110000		
North America	178	96	0.596 (0.393-0.901)		
Europe	279	153	0.848 (0.613-1.173)		200 N
Asia	212	89	0.798 (0.515-1.235)	-	
ECOG PS			the best street streets		
1	264	152	0.757 (0.544-1.053)		
D	400	184	0.750 (0,557-1.010)	-	
Organs Involved, No.			CATTER DIDALATE AND		
23	203	126	0.900 (0.628-1.289)		
2	200	101	0.609 (0.409-0.906)		
1	263	111	0.832 (0.562-1.231)		-
Measurable disease	26-15	19 11 12		1	
Yes	483	255	0.734 (0.569-0.945)		
No	183	83	0.853 (0.545-1.336)		-
Race	1000	100.00	- internet and a state of the		
White	373	214	0.834 (0.633-1.09B)		-
Asian	214	90	0.802 (0.518-1.239)	-	2112
Other	42	12	0.764 (0.085-0.818) +		

Sledge, Jama Oncol 2019

HR (95% CI)

ER+ HER2- Premenopausal MBC pts : Conclusions

- Premenopausal patients (age<49) account for nearly 12% of all incident cases of MBC.
- MBC patients 15-49 old alive:

-at 3.5 y: 48% -at 5 y: 36% -at 10 y: 14%

- In these patients endocrine therapy+ CDK 4/6 inhibitors is the new standard of treatment.
- Ribociclib (+AI+LH-RH) is the preferred option as first line in endocrine sensitive disease (↑OS).
- Abemaciclib or Palbociclib + Fulvestrant (+LH-RH) is the new standard of treatment in CDK 4/6 inhibitors naive patients and endocrine resistant disease.